Vandana Gupta Abramson

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. ncbi request reprint Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling
    Vandana G Abramson
    Department of Medicine, Vanderbilt University School of Medicine, 2220 Pierce Ave, 777 PRB, Nashville, TN, 37232, USA
    Breast Cancer Res Treat 145:389-99. 2014
  2. pmc An algorithm for longitudinal registration of PET/CT images acquired during neoadjuvant chemotherapy in breast cancer: preliminary results
    Xia Li
    Vanderbilt University Institute of Imaging Science, Vanderbilt University, 1161 21st Avenue South, AA 1105 Medical Center North, Nashville, TN 37232 2310, USA
    EJNMMI Res 2:62. 2012
  3. pmc Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome
    Vandana Gupta Abramson
    Department of Medicine, University of Pennsylvania, PA, USA
    Anticancer Res 30:1279-85. 2010
  4. doi request reprint Clinical utility of serum tumor markers and circulating tumor cell assays in the treatment of breast cancer
    Vandana G Abramson
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University, Vanderbilt Ingram Cancer Center, Nashville, TN 37212, USA
    Curr Treat Options Oncol 12:403-11. 2011
  5. pmc Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report
    Wade Iams
    Department of Internal Medicine, Vanderbilt University Medical Center, D 3100 Medical Center North, Nashville, TN 37232 2358, USA
    Med Oncol 30:568. 2013

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling
    Vandana G Abramson
    Department of Medicine, Vanderbilt University School of Medicine, 2220 Pierce Ave, 777 PRB, Nashville, TN, 37232, USA
    Breast Cancer Res Treat 145:389-99. 2014
    ..PIK3CA mutation testing impacted treatment and resulted in more patients entering mutation-specific clinical trials. ..
  2. pmc An algorithm for longitudinal registration of PET/CT images acquired during neoadjuvant chemotherapy in breast cancer: preliminary results
    Xia Li
    Vanderbilt University Institute of Imaging Science, Vanderbilt University, 1161 21st Avenue South, AA 1105 Medical Center North, Nashville, TN 37232 2310, USA
    EJNMMI Res 2:62. 2012
    ..abstract:..
  3. pmc Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome
    Vandana Gupta Abramson
    Department of Medicine, University of Pennsylvania, PA, USA
    Anticancer Res 30:1279-85. 2010
    ..Our objectives were to determine whether cyclin D1b is expressed in human breast carcinomas and to characterize the relationship of this protein to both cyclin D1a and clinical outcome in breast cancer patients...
  4. doi request reprint Clinical utility of serum tumor markers and circulating tumor cell assays in the treatment of breast cancer
    Vandana G Abramson
    Division of Hematology Oncology, Department of Medicine, Vanderbilt University, Vanderbilt Ingram Cancer Center, Nashville, TN 37212, USA
    Curr Treat Options Oncol 12:403-11. 2011
    ..CTCs hold great promise in the management of breast cancer and future studies will help delineate their role more appropriately...
  5. pmc Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report
    Wade Iams
    Department of Internal Medicine, Vanderbilt University Medical Center, D 3100 Medical Center North, Nashville, TN 37232 2358, USA
    Med Oncol 30:568. 2013
    ..We describe herein the case of a patient with stage IIB breast cancer who developed thrombotic microangiopathy after five cycles of carboplatin, docetaxel, and trastuzumab...